Quick Takeaways
- This page summarizes Xiaolin Wang's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 19 Mar 2026, 18:53.
Xiaolin Wang - 17 Mar 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)
- Signature
- /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
- Issuer symbol
- RVMD
- Transactions as of
- 17 Mar 2026
- Net transactions value
- -$199,956
- Form type
- 4
- Filing time
- 19 Mar 2026, 18:53:55 UTC
- Previous filing
- 03 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Xiaolin Wang filed Form 4 for Revolution Medicines, Inc. (RVMD) on 19 Mar 2026."
What Changed
- Previous filing in this sequence was filed on 03 Mar 2026.
- Current net transaction value: -$199,956.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Wang Xiaolin | EVP, Clinical Development | C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY | /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang | 19 Mar 2026 | 0001849181 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RVMD | Common Stock | Sale | $199,956 | -2,010 | -1.7% | $99.48 | 116,063 | 17 Mar 2026 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025. |
| F2 | Includes 48,700 RSUs. |
Remarks:
EVP, Clinical Development